2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Related Products

PDF 4.17 MB

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Phosphodiesterase (PDE) Isoform Specific Products:

Phosphodiesterase (PDE) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100159
    Ipenoxazone
    		Inhibitor
    Ipenoxazone is a potent and centrally acting muscle relaxant.
    Ipenoxazone
  • HY-W050000R
    OR-1855 (Standard)
    		Inhibitor
    Tanshinone IIA sulfonate (sodium) (Standard) is the analytical standard of Tanshinone IIA sulfonate (sodium). This product is intended for research and analytical applications. Tanshinone IIA sulfonate (sodium) is a derivative of tanshinone IIA, which acts as an inhibitor of store-operated Ca2+ entry (SOCE), and is used to treat cardiovascular disorders.
    OR-1855 (Standard)
  • HY-163636
    Deltaflexin3
    		Inhibitor
    Deltaflexin3 is a potent PDE6D inhibitor. Deltaflexin3 reduces the signaling of Ras and selectively decreases the KRAS mutant and PDE6D-dependent cancer cells growth.
    Deltaflexin3
  • HY-100142
    Clozic
    		Inhibitor
    Clozic is a potential anti-arthritic agent.
    Clozic
  • HY-168966
    PDE2 inhibitor 6
    		Inhibitor
    PDE2 inhibitor 6 (Compound 1) is the orally active inhibitor for phosphodiesterase (PDE) that inhibits PDE2A, PDE3B, and PDE10A2 with IC50s of 0.95 nM, 6.17 μM (pIC50=5.21) and 87.1 nM (pIC50=7.06), respectively. PDE2 inhibitor 6 modulates the activity of AMPA receptor, enhance the synaptic plasticity and promotes the learning and memory function in rats models. PDE2 inhibitor 6 can cross blood-brain barrier.
    PDE2 inhibitor 6
  • HY-131545
    Parogrelil
    Parogrelil (NT-702 free base) is a compound with intermittent claudication inhibitory activity that inhibits PDE3, inhibits platelet aggregation and vasoconstriction, and improves walking distance and plantar surface temperature in a rat experimental model.
    Parogrelil
  • HY-147990
    PDE5-IN-5
    		Inhibitor
    PDE5-IN-5 (Compound 11) is a potent, selective phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 2.0 nM.
    PDE5-IN-5
  • HY-145069
    Enpp-1-IN-8
    		Inhibitor
    Enpp-1-IN-8 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-8 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51).
    Enpp-1-IN-8
  • HY-146890
    ATX inhibitor 17
    		Inhibitor
    ATX inhibitor 17 is a potent ATX inhibitor with an IC50 of 0.019 μM. ATX inhibitor 17 shows excellent anti-proliferative activities in breast cancer cells.
    ATX inhibitor 17
  • HY-RS10205
    PDE12 Human Pre-designed siRNA Set A
    		Inhibitor

    PDE12 Human Pre-designed siRNA Set A contains three designed siRNAs for PDE12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PDE12 Human Pre-designed siRNA Set A
    PDE12 Human Pre-designed siRNA Set A
  • HY-14252A
    Milrinone lactate
    		Inhibitor
    Milrinone lactate is a potent inotropic dilating agent. Milrinone lactate shows simultaneous positive inotropic and vasodilating activities. Milrinone lactate promotes reduction of SVR and PVR in patients with DCM and NYHA class III and IV of heart failure. Milrinone lactate has the potential for the research of cardiovascular function after cardiac surgery and in septic shock.
    Milrinone lactate
  • HY-106908
    Filaminast
    		Inhibitor
    WAY-PDA 641 is a potent and preferential PDE-IV inhibitor, with an IC50 of 0.42 μM for canine trachealis PDE-IV. WAY-PDA 641 induces respiratory muscle relaxation and bronchodilation.
    Filaminast
  • HY-19003
    Isomazole
    		Inhibitor
    Isomazole is a new cardiotonic agent. Isomazole increases the calcium sensitivity in atrial fibers and has a direct effect on contractile proteins.
    Isomazole
  • HY-146124
    ATX inhibitor 21
    		Inhibitor
    ATX inhibitor 21 (compound 8) is a potent ATX (autotaxin) inhibitor, with an IC50 of 3490 nM.
    ATX inhibitor 21
  • HY-A0165R
    Tofisopam (Standard)
    		Inhibitor
    Tofisopam (Standard) is the analytical standard of Tofisopam. This product is intended for research and analytical applications. Tofisopam, a 2,3-benzodiazepine compound, is an orally active anxiolytic agent.
    Tofisopam (Standard)
  • HY-113847
    Nanterinone mesylate
    		Inhibitor
    Nanterinone mesylate (UK-61260-27) is an orally active and positive inotropic and balanced-type vasodilating agent, partially based on phosphodiesterase III inhibition with venodilating properties. Nanterinone mesylate is promising for research of cardiovascular diseases.
    Nanterinone mesylate
  • HY-161936
    Z21115
    		Inhibitor
    Z21115 is an orally active inhibitor for phosphodiesterase 4 (PDE4), that inhibits PDE4D7 with IC50 of 10.5 nM. Z21115 inhibits Lipopolysaccharide (HY-D1056)-induced expression of IL-6, TNF-α and iNOS. Z21115 exhibits anti-inflammatory activity in DSS (HY-116282)-induced mouse colitis models without significant toxicity (1 g/kg).
    Z21115
  • HY-122167
    L-869298
    		Inhibitor
    L-869298 is a potent and selective PDE4 inhibitor with an IC50 of 0.5 nM for PDE4A. L-869298 shows less active against hERG potassium channel.
    L-869298
  • HY-144683A
    PF-07038124 hydrochloride
    		Inhibitor
    PF-07038124 hydrochloride is a PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2. PF-07038124 hydrochloride shows inhibitory activities against IL-13, IL4, and IFNγ (IC50=125, 4.1, 1.06 nM, respectively). PF-07038124 hydrochloride can be used for research of atopic dermatitis and plaque psoriasis.
    PF-07038124 hydrochloride
  • HY-N2038R
    3,​5,​6,​7,​8,​3',​4'-​Heptemthoxyflavone (Standard)
    		Inhibitor
    3,​5,​6,​7,​8,​3',​4'-​Heptemthoxyflavone (Standard) is the analytical standard of 3,​5,​6,​7,​8,​3',​4'-​Heptemthoxyflavone (HY-N2038). This product is intended for research and analytical applications. 3,5,6,7,8,3',4'-Heptemthoxyflavone, a flavonoid from satsuma peel, is an orally available CREB activator with anti-tumor and anti-neuroinflammatory activity. 3,5,6,7,8,3',4'-Heptemthoxyflavone inhibits collagenase activity and increases the content of type I procollagen in human dermal fibroblast neoblast (HDFn) cells. 3,5,6,7,8,3',4'-Heptemthoxyflavone induces brain-derived neurotrophic factor (BDNF) expression through the cAMP/ERK/CREB signaling pathway and reduces phosphodiesterase activity in C6 glioma.
    3,​5,​6,​7,​8,​3',​4'-​Heptemthoxyflavone (Standard)
Cat. No. Product Name / Synonyms Application Reactivity
Phosphodiesterase (PDE) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.